Chung Young-Chul, Li Zhu, Dai Jin, Meltzer Herbert Y, Ichikawa Junji
Division of Psychopharmacology, Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, 1601 23rd Avenue South, The First Floor Laboratory Rm-1117, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA.
Brain Res. 2004 Oct 8;1023(1):54-63. doi: 10.1016/j.brainres.2004.07.009.
Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia. This advantage has been attributed, in part, to the ability of the atypical APDs to markedly increase acetylcholine (ACh) and dopamine (DA) release in rat medial prefrontal cortex (mPFC), while producing a minimal effect in the nucleus accumbens (NAC) or striatum. The atypical APD-induced preferential release of DA, but not ACh, in the mPFC is partially inhibited by the selective 5-HT(1A) antagonist WAY100635. However, little is known about these effects of atypical APDs in the ventral hippocampus (vHIP), another possible site of action of atypical APDs with regard to cognitive enhancement. The present study demonstrates that clozapine (10 mg/kg) comparably increases both ACh and DA release in the vHIP and mPFC. The increases in DA, but not ACh, release in both regions were partially attenuated by WAY100635 (0.2 mg/kg), which had no effect by itself on the release of either neurotransmitter in either region. Tetrodotoxin (TTX; 1 microM), a Na(+) channel blocker, in the perfusion medium, eliminated the clozapine (10 mg/kg)-induced ACh and DA release in the vHIP, indicating their neuronal origin. Haloperidol produced a slight increase in ACh release in the vHIP at 1 mg/kg, and DA release in the mPFC at 0.1 mg/kg. In conclusion, clozapine increases ACh and DA release in the vHIP and mPFC, whereas haloperidol has minimal effects on the release of these two neurotransmitters in either region. These differences may contribute, at least in part, to the superior ability of clozapine, compared to haloperidol, to improve cognition in schizophrenia. 5-HT(1A) agonism is important to the ability of clozapine and perhaps other atypical APDs to increase DA, but not ACh, release in the vHIP, as well as the mPFC. The role of hippocampus in the cognitive effects of atypical APDs warrants more intensive study.
非典型抗精神病药物(APDs),如氯氮平,但典型抗精神病药物氟哌啶醇则不然,可改善精神分裂症患者认知的某些方面。这种优势部分归因于非典型APDs能够显著增加大鼠内侧前额叶皮质(mPFC)中的乙酰胆碱(ACh)和多巴胺(DA)释放,而对伏隔核(NAC)或纹状体的影响最小。非典型APD诱导的mPFC中DA而非ACh的优先释放被选择性5-HT(1A)拮抗剂WAY100635部分抑制。然而,对于非典型APDs在腹侧海马(vHIP)中的这些作用知之甚少,vHIP是非典型APDs在认知增强方面另一个可能的作用位点。本研究表明,氯氮平(10 mg/kg)可同等程度地增加vHIP和mPFC中的ACh和DA释放。WAY100635(0.2 mg/kg)部分减弱了这两个区域中DA而非ACh释放的增加,其本身对这两个区域中任何一种神经递质的释放均无影响。灌流液中的钠(Na(+))通道阻滞剂河豚毒素(TTX;1 microM)消除了氯氮平(10 mg/kg)诱导的vHIP中的ACh和DA释放,表明它们来源于神经元。氟哌啶醇在1 mg/kg时使vHIP中的ACh释放略有增加,在0.1 mg/kg时使mPFC中的DA释放略有增加。总之,氯氮平增加vHIP和mPFC中的ACh和DA释放,而氟哌啶醇对这两个区域中这两种神经递质的释放影响最小。与氟哌啶醇相比,这些差异可能至少部分有助于氯氮平在改善精神分裂症认知方面的卓越能力。5-HT(1A)激动作用对于氯氮平以及可能其他非典型APDs增加vHIP以及mPFC中DA而非ACh释放的能力很重要。海马在非典型APDs认知作用中的作用值得更深入研究。